SERPINA3K induces apoptosis in human colorectal cancer cells via activating the Fas/FasL/caspase-8 signaling pathway

FEBS Journal

Volumn 280, Issue 14, 2013, Pages 3244-3255

  Yao, Yachao ^a   Li, Lei ^a   Huang, Xuan ^b   Gu, Xiaoqiong ^c   Xu, Zumin ^d   Zhang, Yang ^e   Huang, Lijun ^a   Li, Shuai ^a   Dai, Zhiyu ^a   Li, Cen ^a   Zhou, Ti ^a   Cai, Weibin ^a   Yang, Zhonghan ^a   Gao, Guoquan ^a,b   Yang, Xia ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

^d GUANGDONG MEDICAL UNIVERSITY   (China)

^e GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

apoptosis; colorectal cancer; FasL; PPAR ; SERPINA3K

Indexed keywords

BINDING PROTEIN; CASPASE 8; FAS ANTIGEN; FAS LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SERPINA3K; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; COLORECTAL CANCER; FASL; PPARΓ; SERPINA3K;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; FAS LIGAND PROTEIN; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; PPAR GAMMA; RNA, SMALL INTERFERING; SERPINS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84879932972     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12303     Document Type: Article

References (65)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, &, Thun MJ, (2009) Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
2. Punt CJ, (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15, 1453-1459.
3. Mancuso A, &, Sternberg CN, (2005) Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice? Crit Rev Oncol Hematol 55, 67-81.
4. Folkman J, (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 15-18.
5. Hanahan D, &, Weinberg RA, (2000) The hallmarks of cancer. Cell 100, 57-70.
6. Kubota Y, (2012) Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 61, 47-56.
7. Chao J, Stallone JN, Liang YM, Chen LM, Wang DZ, &, Chao L, (1997) Kallistatin is a potent new vasodilator. J Clin Invest 100, 11-17.
8. Madeddu P, Emanueli C, &, El-Dahr S, (2007) Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 3, 208-221.
9. Ma JX, Yang Z, Chao J, &, Chao L, (1995) Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem 270, 451-455.
10. Chao J, Chai KX, &, Chao L, (1996) Tissue kallikrein inhibitors in mammals. Immunopharmacology 32, 67-72.
11. Chai KX, Chen VC, Ni A, Lindpaintner K, Rubattu S, Chao L, &, Chao J, (1997) Molecular cloning and expression of rat kallistatin gene. Biochim Biophys Acta 1353, 277-286.
12. Zhang B, Abreu JG, Zhou K, Chen Y, Hu Y, Zhou T, He X, &, Ma JX, (2010) Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci USA 107, 6900-6905.
13. Jin SX, Zeng Y, Wan J, Wan K, Li YY, Li LY, Wang TH, Feng ZT, &, Li Y, (2010) Kallikrein-binding protein promotes axonal regeneration and protects rat retinal ganglion cells following optic nerve injury. Nan Fang Yi Ke Da Xue Xue Bao 30, 738-741.
14. Miao RQ, Agata J, Chao L, &, Chao J, (2002) Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 100, 3245-3252.
15. Gao G, Shao C, Zhang SX, Dudley A, Fant J, &, Ma JX, (2003) Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 46, 689-698.
16. Lu L, Yang Z, Zhu B, Fang S, Yang X, Cai W, Li C, Ma JX, &, Gao G, (2007) Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 257, 97-106.
17. Zhu B, Lu L, Cai W, Yang X, Li C, Yang Z, Zhan W, Ma JX, &, Gao G, (2007) Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 6, 3297-3306.
18. Fernandez-Garcia NI, Volpert OV, &, Jimenez B, (2007) Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med (Berl) 85, 15-22.
19. Chao J, Chai KX, Chen LM, Xiong W, Chao S, Woodley-Miller C, Wang LX, Lu HS, &, Chao L, (1990) Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 265, 16394-16401.
20. Zhou GX, Chao L, &, Chao J, (1992) Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 267, 25873-25880.
21. Chen VC, Chao L, &, Chao J, (2000) Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem 275, 38457-38466.
22. Liu YY, Nakatani T, Kogai T, Mody K, &, Brent GA, (2011) Thyroid hormone and COUP-TF1 regulate kallikrein-binding protein (KBP) gene expression. Endocrinology 152, 1143-1153.
23. Hatcher HC, Ma JX, Chao J, Chao L, &, Ottlecz A, (1997) Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 38, 658-664.
24. Ma JX, King LP, Yang Z, Crouch RK, Chao L, &, Chao J, (1996) Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res 15, 1117-1123.
25. Chao J, Schmaier A, Chen LM, Yang Z, &, Chao L, (1996) Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 127, 612-620.
26. Stadnicki A, Mazurek U, Plewka D, &, Wilczok T, (2003) Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease. Int Immunopharmacol 3, 939-944.
27. White BD, Chien AJ, &, Dawson DW, (2012) Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology 142, 219-232.
28. Yang ZR, Dong WG, Lei XF, Liu M, &, Liu QS, (2012) Overexpression of Dickkopf-3 induces apoptosis through mitochondrial pathway in human colon cancer. World J Gastroenterol 18, 1590-1601.
29. Krysko DV, Vanden BT, D'Herde K, &, Vandenabeele P, (2008) Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 44, 205-221.
30. Zhang T, Guan M, Xu C, Chen Y, &, Lu Y, (2007) Pigment epithelium-derived factor inhibits glioma cell growth in vitro and in vivo. Life Sci 81, 1256-1263.
31. Guan M, Yam HF, Su B, Chan KP, Pang CP, Liu WW, Zhang WZ, &, Lu Y, (2003) Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 56, 277-282.
32. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, &, Crawford SE, (2003) Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 9, 774-780.
33. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, et al,. (2005) Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 65, 5144-5152.
34. Guan M, Jiang H, Xu C, Xu R, Chen Z, &, Lu Y, (2007) Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol Ther 6, 419-425.
35. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE, &, Bergh A, (2004) Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 64, 5664-5671.
36. Cheung LW, Au SC, Cheung AN, Ngan HY, Tombran-Tink J, Auersperg N, &, Wong AS, (2006) Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 147, 4179-4191.
37. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP, &, Donis-Keller H, (1996) Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 56, 606-611.
38. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Hase R, Takahashi R, Mega S, et al,. (2004) Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 64, 3533-3537.
39. Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, Watanabe H, Sugawara H, Nakamura H, Takeuchi M, et al,. (2004) Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 164, 1225-1232.
40. Garcia M, Fernandez-Garcia NI, Rivas V, Carretero M, Escamez MJ, Gonzalez-Martin A, Medrano EE, Volpert O, Jorcano JL, Jimenez B, et al,. (2004) Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 64, 5632-5642.
41. Yang H, Xu Z, Iuvone PM, &, Grossniklaus HE, (2006) Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 12, 511-517.
42. Guan M, Pang CP, Yam HF, Cheung KF, Liu WW, &, Lu Y, (2004) Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 11, 325-332.
43. Cui FY, Song XR, Li ZY, Li SZ, Mu B, Mao YQ, Wei YQ, &, Yang L, (2010) The pigment epithelial-derived factor gene loaded in PLGA nanoparticles for therapy of colon carcinoma. Oncol Rep 24, 661-668.
44. Konson A, Pradeep S, &, Seger R, (2010) Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents. Cancer Res 70, 6247-6257.
45. Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, &, Srivastava S, (2000) p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 275, 6051-6054.
46. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knuchel R, Kondo M, Jonas U, et al,. (2001) Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer 95, 337-342.
47. Shi HY, Zhang W, Liang R, Kittrell F, Templeton NS, Medina D, &, Zhang M, (2003) Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol 18, 201-206.
48. Schaefer JS, &, Zhang M, (2003) Role of maspin in tumor metastasis and angiogenesis. Curr Mol Med 3, 653-658.
49. Cher ML, Biliran HJ, Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M, &, Sheng S, (2003) Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 100, 7847-7852.
50. Liu Y, Geng Y, Li K, Wang F, Zhou H, Wang W, Hou J, &, Liu W, (2012) Comparative proteomic analysis of the function and network mechanisms of MASPIN in human lung cells. Exp Ther Med 3, 470-474.
51. Bishop-Bailey D, (2011) PPARs and angiogenesis. Biochem Soc Trans 39, 1601-1605.
52. Debril MB, Renaud JP, Fajas L, &, Auwerx J, (2001) The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med (Berl) 79, 30-47.
53. Rubin GL, Zhao Y, Kalus AM, &, Simpson ER, (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60, 1604-1608.
54. Chattopadhyay N, Singh DP, Heese O, Godbole MM, Sinohara T, Black PM, &, Brown EM, (2000) Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 61, 67-74.
55. Tyagi S, Gupta P, Saini AS, Kaushal C, &, Sharma S, (2011) The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2, 236-240.
56. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, &, Eng C, (1999) Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3, 799-804.
57. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, et al,. (2009) Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136, 1242-1250.
58. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, et al,. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4, 1046-1052.
59. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, &, Hosokawa M, (2001) Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 61, 2424-2428.
60. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, &, Evans RM, (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4, 1058-1061.
61. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, &, Auwerx J, (1998) Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4, 1053-1057.
62. Auwerx J, (2002) Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain? Am J Physiol Gastrointest Liver Physiol 282, G581-G585.
63. Lin MS, Chen WC, Bai X, &, Wang YD, (2007) Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J Dig Dis 8, 82-88.
64. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, &, MacDougald OA, (2000) Inhibition of adipogenesis by Wnt signaling. Science 289, 950-953.
65. Perobner I, Karow M, Jochum M, &, Neth P, (2012) LRP6 mediates Wnt/beta-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells. Int J Biochem Cell Biol 44, 1970-1982.